Real-World Data of Microvascular Decompression in Trigeminal Neuralgia: Analysis of 26 Tertiary Care Centers of the European Continent

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13450%2F23%3A43898622" target="_blank" >RIV/44555601:13450/23:43898622 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.researchgate.net/publication/369702269_135_Real-World_Data_of_Microvascular_Decompression_in_Trigeminal_Neuralgia_Analysis_of_26_Tertiary_Care_Centers_of_the_European_Continent" target="_blank" >https://www.researchgate.net/publication/369702269_135_Real-World_Data_of_Microvascular_Decompression_in_Trigeminal_Neuralgia_Analysis_of_26_Tertiary_Care_Centers_of_the_European_Continent</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1227/neu.0000000000002375_135" target="_blank" >10.1227/neu.0000000000002375_135</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-World Data of Microvascular Decompression in Trigeminal Neuralgia: Analysis of 26 Tertiary Care Centers of the European Continent

Popis výsledku v původním jazyce

INTRODUCTION Patients with classic trigeminal neuralgia (TN) usually receive first-line treatment with carbamazapine. The known effect of wearing-off is hold against the result of expert single-center series of microvascular decompression (MVD) as a successful treatment option. However, real-world data regarding MVD is lacking. METHODS A multicenter retrospective data analysis was performed in 26 European hospitals. Inclusion criteria were a) age &gt;18 to 85 years, b) patients with classical TN, c) patients who underwent microvascular decompression (MVD) and d) minimum follow-up of 12 months. Primary outcome is pain-freedom at last follow up. Secondary outcome parameters were duration of symptoms prior to MVD, neurovascular conflict in MRI, time to pain recurrence, complications, and a tailored questionnaire. RESULTS 1140 patients from 26 European institutions were analysed. Of those, 591 (346 female, 245 male, age (mean?SD) 60.1 ? 13.4 years) fulfilled the inclusion criteria. Mean duration of symptoms prior to surgery was 73.3 ? 67.0 months (6.1 ? 5.6 years). 73.3% of patients had a visible neurovascular conflict in MRI. After a follow-up 49.9 ? 36.8 months, 68.7% of patients were pain free or had occasional pain (BNI score 1 and 2). There was no correlation between symptom duration and time to pain recurrence. Involvement of SCA (61%) was associated with a high probability of pain freedom (p&lt;0.01). Complications occurred in 31.6% of all cases, with hypoesthesia of the facial nerve being the most common event. Three out of four patients (74%) were satisfied with the treatment, and 72% would choose MVD as the preferred treatment option again. CONCLUSIONS Microvascular decompression for trigeminal neuralgia is an effective treatment modality with excellent pain control. Two-third of patients were satisfied with the treatment.

Název v anglickém jazyce

Real-World Data of Microvascular Decompression in Trigeminal Neuralgia: Analysis of 26 Tertiary Care Centers of the European Continent

Popis výsledku anglicky

INTRODUCTION Patients with classic trigeminal neuralgia (TN) usually receive first-line treatment with carbamazapine. The known effect of wearing-off is hold against the result of expert single-center series of microvascular decompression (MVD) as a successful treatment option. However, real-world data regarding MVD is lacking. METHODS A multicenter retrospective data analysis was performed in 26 European hospitals. Inclusion criteria were a) age &gt;18 to 85 years, b) patients with classical TN, c) patients who underwent microvascular decompression (MVD) and d) minimum follow-up of 12 months. Primary outcome is pain-freedom at last follow up. Secondary outcome parameters were duration of symptoms prior to MVD, neurovascular conflict in MRI, time to pain recurrence, complications, and a tailored questionnaire. RESULTS 1140 patients from 26 European institutions were analysed. Of those, 591 (346 female, 245 male, age (mean?SD) 60.1 ? 13.4 years) fulfilled the inclusion criteria. Mean duration of symptoms prior to surgery was 73.3 ? 67.0 months (6.1 ? 5.6 years). 73.3% of patients had a visible neurovascular conflict in MRI. After a follow-up 49.9 ? 36.8 months, 68.7% of patients were pain free or had occasional pain (BNI score 1 and 2). There was no correlation between symptom duration and time to pain recurrence. Involvement of SCA (61%) was associated with a high probability of pain freedom (p&lt;0.01). Complications occurred in 31.6% of all cases, with hypoesthesia of the facial nerve being the most common event. Three out of four patients (74%) were satisfied with the treatment, and 72% would choose MVD as the preferred treatment option again. CONCLUSIONS Microvascular decompression for trigeminal neuralgia is an effective treatment modality with excellent pain control. Two-third of patients were satisfied with the treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurosurgery

ISSN

0148-396X

e-ISSN

1524-4040

Svazek periodika

69

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

34

Kód UT WoS článku

001043164400040

EID výsledku v databázi Scopus

—